Compare Incyte Corporation (INCY) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs TJX Companies Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while TJX Companies Inc trades at $138.76 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 6.7× Incyte Corporation's market cap, and TJX Companies Inc pays a 1.38% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and TJX Companies Inc for 97 Days on average.
| INCY | TJX | |
|---|---|---|
Market Cap | $22.85B | $152.62B |
Volume | 1,927,029 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $168.41 |
52-Week Low | $83.80 | $122.84 |
Typical Hold Time | 33 Days | 97 Days |
Enterprise Value | $18.35B | $160.93B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
TJX trades at $138.76, down slightly by 0.03% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals, with revenue rising to $56.36B in 2025 and net income reaching $4.86B, alongside robust profitability metrics like a 62.17% ROE. Recent quarterly earnings have consistently beaten expectations, and the firm maintains a solid balance sheet with manageable debt levels.
The outlook for TJX is positive, supported by Wall Street's strong buy consensus (84.9% buy ratings) and a $174.15 price target implying 28% upside. Key risks include competitive pressures in off-price retail and sensitivity to consumer spending trends. Investor sentiment is buoyed by earnings momentum and expansion potential, though overbought technical conditions may prompt near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
